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Abstract: This study was designed to investigate the effect of increased levels of HO-1
on hypertension exacerbated by diabetes. Diabetic spontaneously hypertensive rat (SHR)
and WKY (control) animals were treated with streptozotocin (STZ) to induce diabetes
and stannous chloride (SnCl2) to upregulate HO-1. Treatment with SnCl2 not only
attenuated the increase of blood pressure (p<0.01), but also increased HO-1 protein
content, HO activity and plasma adiponectin levels, decreased the levels of superoxide
and 3-nitrotyrosine (NT), respectively. Reduction in oxidative stress resulted in the
increased expression of Bcl-2 and AKT with a concomitant reduction in circulating
endothelial cells (CEC) in the peripheral blood (p<0.005) and an improvement of femoral
reactivity (response to acetylcholine). Thus induction of HO-1 accompanied with
increased plasma adiponectin levels in diabetic hypertensive rats alters the phenotype
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through a reduction in oxidative stress, thereby permitting endothelial cells to maintain an
anti-apoptotic environment and the restoration of endothelial responses thus preventing
hypertension.
Keywords: Heme oxygenase; hypertension; diabetes; adiponectin; oxidative stress;
apoptosis.

1. Introduction
Cardiovascular and renal disease are the leading causes of morbidity and mortality in patients with
diabetes [1]. Hypertension is an independent risk factor for both macrovascular (stroke, myocardial
infarct, peripheral vascular disease) and microvascular (nephropathy, neuropathy, retinopathy)
complications and is a common co-existing condition in diabetes [1]. Oxidative stress has been
implicated in the pathogenesis of insulin resistance, type 2 diabetes, and its cardiovascular
complications [2, 3]. Excessive generation of reactive oxygen species (ROS) in diabetes is the
underlying mechanism of endothelial injury, resulting in an accelerated rate of apoptosis and
endothelial cell sloughing [4,5]. Oxidative stress underlies hypertension in many animal models [6].
Superoxide (O2-) raises blood pressure (BP) by both central [7] and peripheral mechanisms [8]. Recent
studies indicate that the combination of diabetes and hypertension adversely affects oxidative stress in
the kidney [9, 10], this is associated with the high prevalence of chronic kidney disease . In the 1999
to 2000 National Health and Nutrition Examination Survey (NHANES), 40.4% of people with diabetes
had hypertension [11]. In patients with newly diagnosed diabetes, hypertension is associated with a
56% increased risk for cardiovascular morbidity and mortality [12]. Even prehypertension, which is a
more prevalent (59.4% vs. 48.2%, P <0.001) in patients with diabetes, confers additional
cardiovascular risk. Compared with controls, in patients with diabetes with and without
prehypertension, the hazard ratios for developing cardiovascular disease are 3.70 and 2.90,
respectively [13]. One central therapeutic approaches to prevent diabetic and hypertensive organ
damage is strict blood glucose control, however blood pressure must also be rigorously controlled [14].
Therefore, in order to develop a drug with therapeutic efficacy as an antihypertension and antidiabetes
agent is of great importance that it should have renoprotective properties.
The heme oxygenase (HO) system displays both antioxidant and anti-apoptotic properties because
of its degradation products, bilirubin/biliverdin and carbon monoxide (CO), respectively [15]. The
beneficial effects of upregulation of HO-1 in antihypertension, antidiabetes and renoprotection have
been reported in a series animal models [15]. The HO system has been implicated in the regulation of
blood pressure and the blood pressure lowering effect of HO-1 induction has been attributed to various
mechanisms, including decreased production of vasoconstrictor eicosanoids and increased production
of CO [15]. CO is a vasodilator, a stimulator of soluble guanylate cyclase, an endogenous modulator of
the cGMP signaling system, an activator of calcium-activated potassium channels (KCa) in vascular
smooth muscle and an inhibitor of endothelin-1 mediated vasoconstriction [15-17]. HO has been
reported to be involved in the regulation of renal salt excretion. CO generated by HO-dependent heme
catabolism stimulates the apical 70-pS K-channel [18]. Inhibition of HO activity decreases sodium and
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fluid reabsorption in the thick ascending limb of the loop of Henle in the rat [19]. Furthermore,
exogenous heme administration induces HO-dependent natriuresis and diuresis which were blocked by
SnMP pretreatment [20]. These reports reinforce the potential importance of HO in the regulation of
kidney function. However, no study has examined the role of HO-1 in an animal model with both
hypertension and diabetes.
The objective of this study was to examine HO-1 induction in relation to the renal HO system,
plasma adiponectin levels, endothelial function, the extent of endothelial cell sloughing, oxidant levels
and blood pressure in a diabetic hypertensive animal model (SHR). Our results demonstrate that basal
levels of the constitutively expressed HO-2 are not increased, but O2- and nitrotyrosine levels were
increased in SHR compared to Wistar-Kyoto (WKY) rats. Administration of stannous chloride
(SnCl2), a potent inducer of HO-1 protein and HO activity, attenuated the development of
hypertension. This was associated with the elevation of plasma adiponectin levels, decreased
endothelial apoptosis, oxidative and nitrosative stress and increased production of CO and bilirubin,
thereby demonstrating a significant role for HO-1 in cellular defense against endothelial dysfunction,
oxidant damage and the maintenance of renal hemodynamic function in the diabetic hypertensive
animal model. These findings have important clinical implications in the management of hypertension
in the diabetic patients.
2. Results and Discussion
This is the first study suggests the existence of an HO-1-adiponectin axis that is central to lowering
blood pressure in diabetic SHRs. In the present study, increased renal HO-1 expression and HO
activity with a concomitant increase in plasma adiponectin levels resulted in a reduction in the level of
hypertension as manifest by a decrease in blood pressure in a diabetic hypertensive animal model. In
addition, the diabetes-mediated increase in contractility in femoral arteries and CECs in peripheral
blood was reversed by increase in HO-1 expression and HO activity. The upregulation of HO-1 was
associated with a concomitant decrease in the levels of O2- and 3-NT, markers for oxidative stress. In
addition, there was an increase in the expression of the anti-apoptotic proteins, Bcl-2 and AKT. Thus,
it appears that the induction of renal HO-1 combined with increased plasma adiponectin levels in the
diabtetic SHR animal model results in a change of phenotype from pro- to anti-apoptotic.
2.1. Effect of SnCl2 on HO-1 and HO-2 expression in SHR and WKY rats
Figures 1A-C depict the inducing effect of SnCl2 (50 mg/kg bw s.c.), as manifest by an increase in
the levels of renal HO-1 protein in both SHR and WKY rats (Figures 1A and B). In addition, we
examined the effect of diabetes on the expression of HO-1 and HO-2 in rat kidneys. As seen in Figures
1A and B, SnCl2 caused significant increases in the levels of HO-1 protein, but not in HO-2 protein in
both SHR and WKY rats. Furthermore, HO activity increased from 0.16 nmol/hr/mg protein in the
kidneys of WKY animals to 0.24 nmol/hr/mg protein in SnCl2-treated animals and from 0.13
nmol/hr/mg protein in the kidneys of diabetic SHR to 0.42 nmol/hr/mg protein in SnCl2-treated
animals after four days of administration (Figure 1C).

Int. J. Mol. Sci. 2008, 9

2391

Figure 1. A) Western blot and densitometry analysis of HO-1 and HO-2 proteins in kidney
from WKY rats or SHRs. Rats were treated with SnCl2 (once a week 50 mg/kg body
weight for 4 weeks, S.C.), STZ (once a week 65 mg/kg body weight for 4 weeks i.v. for
diabetic models) or both SnCl2 and STZ. Immunoblots were performed with antibodies
against rat HO-1 and HO-2. Data are representative of 4 separate experiments. B) Mean
band density normalized relative to β-actin (n=4, * p<0.05 vs. WKY control rats, * *
p<0.05 vs. WKY DM (diabetic models), # p<0.05 SHR control, † p<0.05 vs. SHR DM ). C)
HO activity in kidney from WKY rats or SHRs (n=4, * p<0.05 vs. corresponding
control rats).

2.2. Effect of HO inducers on COX-2 in the diabetic kidney
HO-1 induction is associated with a reciprocal decrease in arachidonic acid metabolism by
cytochrome P450 (CYP450) monoxgenases and cyclooxygenases (COX) and to a decrease in blood
pressure in SHR, therefore we measured the expression of COX-2 in the kidneys of SHR and WKY
rats. Western blot analysis revealed significantly (p<0.05) higher levels of COX-2 protein expression
in both diabetic WKY and SHR animals compared to control rats (data not shown). SnCl2
administration resulted in a decrease in the levels of COX-2 expression in the kidneys of both animal
groups. In both the WKY and SHR SnCl2-treated animals, the levels of COX-2 expression returned to
control levels (data not shown). SnCl2 administration had no effect on COX-2 expression in
nondiabetic animals.

Int. J. Mol. Sci. 2008, 9

2392

2.3. Effect of HO-1 induction on plasma adiponectin levels
To understand the possible mechanism by which HO-1 mediated increase in antioxidants levels, we
measured adiponectin levels. There was a significant decrease in plasma adiponectin levels in diabetic
SHRs compared to SHR controls (Figure 2). SnCl2 administration resulted in a marked increase in the
levels of plasma adiponectin in diabetic SHRs as compared to diabetic untreated animals (Figure 2).
Moreover, plasma adiponectin in diabetic SHRs attained levels similar to those in the WKY control
animals (Figure 2).
Figure 2. Plasma adiponectin levels of WKY rats and SHRs (* p<0.05 vs. WKY control
and SHR control respectively, # p<0.01 vs. WKY control and SHR DM + SnCl2
respectively, ** p<0.05 vs. WKY control and SHR DM + SnCl2, respectively).

Figure 3. O2- production levels of kidney and western blot analysis of nitrotyrosine in
SHRs (* p<0.05 vs. SHR control, # p<0.05 vs. SHR DM).
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2.4. Effect of HO-1 induction on O2- production in the kidney
O2- production was assessed in the kidneys of SHR animals using a low concentration of lucigenin
(5 µm). As seen in Figure 3, kidneys obtained from diabetic SHR show a significant increase in O2-.
SnCl2 administration resulted in a decrease in O2- levels in SHR control animals. This decrease
paralleled the decrease in COX-2 levels but was the reciprocal of the increase in HO activity and HO-1
levels described above (Figure 1 A-C).
2.5. Effect of HO inducers on nitrotyrosine levels
Nitrotyrosine (3-NT) levels were measured using Western blot analysis and untreated diabetic rats
showed increased levels of 3-NT. Treatment of diabetic animals with SnCl2 resulted in a decrease in 3NT to levels lower than those in controls (Figure 3). SnCl2 administration had no effect on 3-NT levels
in nondiabetic SHR. (Figure 3).
2.6. Effect of HO expression on the development of hypertension
Systolic blood pressure was significantly (p<0.05) increased in SHR compared to WKY rats. In
diabetic WKY rats, SnCl2 treatment resulted in a small but significant (p<0.05) decrease in blood
pressure compared to controls (Figure 4). In the untreated diabetic SHR, systolic blood pressure was
significantly higher than that of the SHR controls (154 ± 11 mmHg vs. 128 ± 8 mmHg, p<0.05)
(Figure 4). Treatment with SnCl2 resulted in a decrease in systolic blood pressure in diabetic SHR to
levels of the SHR controls (Figure 4).
Figure 4. A and B. Blood pressure was measured by the tail cuff method after the
treatment (* p<0.05 vs. WKY DM, ** p<0.05 vs. WKY control, # p<0.05 vs. SHR control,
†
p < 0.05 vs. SHR DM).
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2.7. Effect of HO-1 expression on vascular responses to PE and Ach
To assess the effect of HO-1 expression on vascular response, we measured PE-induced contraction
and ACh-induced relaxation in the femoral artery. A significant increase in contraction and impairment
of relaxation was observed in SHR compared to normal WKY rats (Figures 5A and B, respectively).
SnCl2 treatment restored vascular reactivity in diabetic WKY rats to normal levels (Figures 5C and
5D). In addition, not only was the contraction in treated diabetic SHR decreased (Figure 6A) but the
relaxation was increased compared to untreated rats (Figure 6B), suggesting the existence of
endothelial cell damage in hypertensive rats and that HO-1 induction not only restores but also
improves endothelial dysfunction.
Figure 5. A) The ring segments from femoral arteries were exposed to phenylephrine (PE)
in a dose-dependent manner (10-8 -10-4 M). PE-induced contraction of SHRs was
significantly increased as compared to WKY rats (*p<0.05 vs. WKY control rats). B)
Femoral arteries were precontracted with phenylephrine (PE) and then exposed to
acetylcholine (Ach) in a dose dependent manner (10-9 -10-5 M). Vessels from SHRs
demonstrated a decreased response compared to WKY rats. C) The ring segments from
femoral arteries were exposed to phenylephrine (PE) in a dose-dependent manner (10-8 -104
M). PE-induced contraction of WKY rats treated with STZ was significantly increased as
compared to control rats, this increase was fully reversed in WKY rats treated with STZ
and SnCl2 (*p<0.05 vs. WKY control rats). D) Femoral arteries were precontracted with
phenylephrine (PE) and then exposed to acetylcholine (Ach) in a dose dependent manner
(10-9 -10-5 M). Vessels from WKY rats treated with STZ demonstrated a decreased
response compared to control rats significantly, which was fully reversed by SnCl2
treatment (*p<0.05 vs. WKY control rats, # p<0.05 vs.WKY DM rats).
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Figure 6. A) The ring segments from femoral arteries were exposed to phenylephrine (PE)
in a dose-dependent manner (10-8 -10-4 M). PE-induced contraction of SHRs treated with
STZ was significantly increased as compared to control rats. With SnCl2 administration,
the contraction in SHRs treated with STZ was more decreased compared to control rats
(*p, †p<0.05 vs. SHR control, #p<0.05 vs. DM rats). B) Femoral arteries were
precontracted with phenylephrine (PE) and then exposed to acetylcholine (Ach) in a dose
dependent manner (10-9 -10-5 M). Vessels from SHRs treated with STZ demonstrated a
decreased response compared to control rats significantly, which was reversed by SnCl2
administration (*p<0.05 vs. SHR control, #p<0.05 vs. DM rats).

Figure 7. Number of circulating endothelial cells in control and diabetic rats was measured.
Number of cells in SHR controls increased significantly compare to WKY control rats.
STZ treatment increased the cells significantly in WKY rats and SHRs relative to controls.
Administration of SnCl2 decreased circulating endothelial cells in WKY DM rats, SHR
control and SHR DM, but had no significant effect in WKY control rats (*p<0.05 vs.
WKY control rats, * * p<0.05 vs. WKY DM rats, #p < 0.05 vs. SHR control rats, †p < 0.05
vs. SHR DM ).
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2.8. Endothelial cell sloughing
Because endothelial cell sloughing is related to endothelial damage, CEC were isolated from
peripheral blood and counted. Cells were counted if they had at least 10 immunomagnetic beads
attached, fluoresced under ultraviolet light after staining with acridine orange, and maintained the
round to oval shape and the 20-50 µm size typical of endothelial cells. As seen in Figure 7, the number
of CEC was significantly higher in diabetic animals compared to controls. Treatment with SnCl2
reduced the number of CEC in both diabetic SHR and WKY animals, reflecting the existence of
endothelial damage in hypertensive animals (Figure 7).
2.9. Effect of HO-1 induction on Bcl-2 in SHR and WKY rats
We examined the levels of Bcl-2, an anti-apoptotic protein, since oxidative stress results in the
activation of multiple signaling cascades that ultimately dictate the outcome for cell survival. As seen
in Figures 8A and B, Bcl-2 expression was significantly decreased in diabetic animals compared to
controls. Treatment with SnCl2 restored the levels of Bcl-2 in both diabetic SHR and WKY animals. A
similar response was seen with AKT (results not shown).
Figure 8. A and B. Western blot and densitometry analysis of anti-apoptotic Bcl-2 in
kidney from WKY rats (A, * P<0.05 vs. WKY DM rats) or SHRs (B, * p<0.05 vs. SHR
control, #p<0.05 vs. SHR DM). Mean band density normalized relative to β-actin.
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The dramatic change in phenotype described above was highlighted by the decrease in the number
of CEC in the peripheral blood of SnCl2-treated diabetic animals when compared to control diabetic
animals. Diabetes increases contractility in femoral arteries; however, in the present study, contractility
was reversed by the induction of renal HO-1. Indeed, in diabetic animals, HO-1 induction resulted in
the restoration of contractility to pre-diabetic levels in both SHR and WKY animals. Increased
relaxation to Ach after CoPP treatment has been reported using the femoral artery model [21]. CoPP,
like SnCl2, is a powerful inducer of HO-1. Increased relaxation has also been achieved by the use of
the CO-releasing molecule CORM-3, but not with the antioxidant heme-degradation product,
biliverdin [21]. Recently, we reported that HO-1 upregulation by CoPP prevents the diabetic state in
non-obese diabetic (NOD) mice [22]. Also, exogenously administered CO and bilirubin both can
prevent endothelial cell sloughing in diabetic rats, presumably via a decrease in oxidative stress, and
thus represent a novel approach to prophylactic vascular protection in diabetes [23]. To examine the
impact of HO-1 expression on the vascular system, PE-induced contraction and Ach-induced
relaxation were measured in the femoral artery. A significant increase in contraction and impairment
of relaxation was observed in hypertensive animals when compared to WKY control animals (Figure
5). The administration of SnCl2 to hypertensive animals resulted in both a decrease in contraction and
an increase in relaxation compared to untreated animals (Figure 6). Thus, it appears that increased
renal HO-1 expression not only restores endothelial cell function but also improves pre-existing
endothelial damage in the SHR animal model of diabetes. Indicating the seminal role of HO-1 in both
preventing and reversing diabetes-induced endothelial dysfunction in this animal model. Thus, the use
of HO inducers may be of clinical benefit in individuals with significant endothelial cell dysfunction in
an attempt to correct existing clinical deficits. Also, the beneficial effects of HO-1 overexpression on
blood glucose in this animal model of diabetes encourages the development of this approach in the
clinical arena.
Hyperglycemia-mediated increases in O2- formation and ROS contribute to endothelial and beta cell
apoptosis and dysfunction. These defects may be reversed by the overexpression of antioxidant
enzymes and the administration of antioxidants. In the present study, overexpression of HO-1 resulted
in decreased O2- generation, which may be due to a decrease in the levels of NADPH oxidase [24], a
heme-dependent protein, and/or an increase in the levels of EC-SOD [25]. In addition, the heme
degradation products, CO and bilirubin, have, respectively, potent anti-inflammatory and antiapoptotic activities and antioxidant properties [15]. Thus, the induction of HO-1 appear to provide a
favorable cellular environment for survival that is rich in antioxidants. Indeed, HO-1 overexpression
results in a phenotype that is both anti-oxidative and anti-apoptotic. Our results show that generation of
O2- was prevented by increased renal HO-1 expression in diabetic SHRs. This was associated with
concomitant decreases in O2-, 3-NT and COX-2 expression and increases in Bcl-2 and
AKT expression.
Renal medullary HO activity plays an essential role in the control of pressure natriuresis and arterial
blood pressure and that impairment of this HO/CO-mediated antihypertensive mechanism results in the
development of hypertension [26]. Kidney-specific induction of HO-1 prevents the development of
Ang II-dependent hypertension and that induction of HO-1 in the kidney may be the mechanism by
which systemic delivery of HO-1 inducers lowers blood pressure in Ang II-dependent hypertension
[27]. 3-nitrotyrosine, cellular heme and superoxide, all promoters of vascular damage, are reduced by
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HO-1 induction, thereby preserving vascular integrity and protecting renal function through a decrease
in blood pressure and an increase in antiapoptotic proteins. In contrast, inhibition of HO activity
exacerbated renal damage in a renovascular hypertension animal model [28,29]. Upregulation of HO1-linked signaling pathways and reversal of vascular remodeling in peripheral blood vessels likely
mediate the antihypertensive effect of hemin [30]. Human HO-1 gene transfer lowers blood pressure
and promotes growth in spontaneously hypertensive rats [31]. Upregulation of HO-1 prevents the
generation of oxidative stress only when the anti-oxidant defense system is operative [32]. Individuals
with low levels of HO-1 (caused by HO-1 genetic polymorphism) are more likely to have renal injury
and express a hypertensive phenotype following chronic ingestion of low-level Cd, compared with
those having higher levels of HO-1 [33]. HO-1 is essential for the antiproliferative and vascular
protective effects of rapamycin in vitro and in vivo in monocrotaline-induced pulmonary hypertension
[34]. The mesenteric vasodilator action of 11,12-EET mediated vascular relaxation is via an increase in
HO activity and activation of calcium-activated potassium channels [35]. CO releasing molecules
(CO-RMs) are effective therapeutic agents that deliver CO during kidney cold preservation and can be
used to ameliorate vascular activity, energy metabolism and renal function at reperfusion [36]. It has
been reported that bilirubin may effect the DOCA-salt model of systemic hypertension [37]. The
pressor and pro-oxidant effects of Ang II are attenuated in the hyperbilirubinemic rat, an effect which
may reflect scavenging of superoxide anion by bilirubin [38]. In agreement with these results, our
previous studies demonstrated higher levels of HO-1 in the renal medulla thus reinforcing the role of
the HO/CO system in the regulation of renal medullary blood flow. HO-1 in mTAL plays a vital role
in protecting against various noxious stimuli [39,40]. In the glycerol model of acute renal failure,
increased release of heme proteins caused renal toxicity whereas pre-induction of HO-1 preserved
renal function [41]. The protective actions of HO-1 are not confined to the attenuation of oxidant
levels, but extend to amelioration of inflammation, atherosclerosis, transplant pathobiology and
ischemia [15].
Abraham's group found that upregulation of HO-1 can increase adiponectin levels in several animal
models [42-46]. The beneficial effects of adiponectin in a variety of cardiovascular diseases have been
reviewed [47, 48], especially there is a negative relationship between adiopnectin and hypertension
[49]. The mechanism by which HO-1 is involved in increased adiponectin levels is related to the
function of HO-1 as a stress response/chaperone protein as well as its ability to decrease ROS by
increasing glutathione and EC-SOD levels [5, 15, 25] and by decreasing O2- production [42, 50].
PPARγ agonists, are shown to induce both HO-1 [51] and the rate-limiting chaperone protein EroL
[52,53]. PPARγ agonist which increases adiponectin may do so by increasing the levels of EroL
chaperone protein [52]. Since PPARγ also increases HO-1 protein levels [51] and HO-1 is known as a
chaperone protein, it is possible that one of the mechanisms by which HO-1 can increase adiponectin
levels is through more efficient adiponectin stabilization and protection. This would confirm the report
of Wang et al who showed that the chaperone protein EroL increased adiponectin [53]. We also have
previously shown that upregulation of HO-1 protein in diabetic rats provided both cardio- and
vascular- protection against ROS [42].
Taken together, the results of the present study demonstrate that upregulation of renal HO-1
associated with increased adiponectin can prevent diabetes-induced vascular dysfunction in the SHR
model of diabetes. The HO-1-mediated increase in adiponectin resulted in a decrease in blood

Int. J. Mol. Sci. 2008, 9

2399

pressure, a decrease in the number of circulating endothelial cells and restoration of endothelial
function in diabetic SHR animals. Indeed, renal HO-1 overexpression can restore pre-existing
damaged endothelial cell function. Overexpression of renal HO-1 was associated with a concomitant
decrease in the levels of O2-, 3-NT and COX-2 and an increase in the levels of the anti-apoptotic
proteins Bcl-2 and AKT. The clinical significance of these observations can not be overestimated
(summarized in Figure 9) as the pharmacological enhancing of HO-1 expression, resulting in increase
of HO activity and adiponectin levels, allows the endothelial system to initiate a crucial and immediate
host defense against diabetes-mediated perturbations in cellular viability due to increased levels of
oxidative stress, thereby preventing the occurrence of high blood pressure and deleterious
perturbations in renal function.
Figure 9. Potential mechanisms underlying the chemoprotective actions of HO-1 in
diabetes and hypertension.
DM / Hypertension

HO-1
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Bilirubin
Heme
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O2 -
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Endothelial Cell Sloughing
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Vascular Reactivity
These observations in DM hypertensive rats suggest that pharmacological
induction of HO-1 attenuates oxidative stress by increasing adiponectin,
decreasing cellular heme and the inducible COX-2 levels and increasing
anti-apoptotic Bcl-2.

3. Experimental Section
3.1. Animals: induction of diabetes and treatments
Male spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats, 180-220 g were used
in this study. Diabetes was induced by a single injection of streptozotocin (STZ) (65 mg/kg bw) via the
tail vein. STZ was dissolved in 0.05 mol/L sodium citrate buffer (pH 4.5). Age-matched control rats
were injected with an equal volume of vehicle (sodium citrate buffer). Rats administered STZ
developed hyperglycemia within three days with glucose levels reaching 475±65 mg/dL. To alleviate
extreme hyperglycemia and to maintain normal body weight, insulin (NPH 1-3 U/day/100 g bw) was
administered three times a week, maintaining glucose levels at 250-300 mg/dL [54]. Glucose was
determined (Lifescan, Milpitas, CA) using blood obtained from the tail vain via a capillary tube. All
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samples were obtained after an overnight fast. Stannous chloride (SnCl2) administration commenced
the day after diabetes developed. SnCl2 (5 mg/100 g bw) was given subcutaneously (s.c.) once a week
for four weeks. Systolic blood pressure was measured without anesthesia, using the tail cuff method, at
least twice at the baseline and before sacrifice, respectively. Rats were divided into groups as follows:
control, STZ, SnCl2 and STZ plus SnCl2. The Institutional Animal Care and Use Committee approved
all experiments, which were conducted under the guidelines for the Care and Use of Laboratory
Animals from the National Institutes of Health (NIH).
3.2. Tissue preparation
Frozen kidneys were pulverized under liquid nitrogen and placed in a homogenization buffer (10
mM phosphate buffer, 250 mM sucrose, 1 mM EDTA, 0.1 mM PMSF and 0.1% tergitol, pH 7.5).
Homogenates were centrifuged at 27,000 g for 10 min at 4ºC. The supernatant was isolated and protein
levels were determined by the Bradford method. The supernatant was used for measurement of HO-1
and HO-2, COX-2, AKT and Bcl-2 protein and HO activity [43].
3.3. Western blot analysis
Protein levels were visualized by immunoblotting with antibodies against rat HO-1 and HO-2
(Stressgen Biotechnologies, Victoria, BC), AKT and Bcl-2 (Cell Signaling Technology, Danvers,
MA), COX-2 (Cayman Chemical, Ann Arbor, MI). Briefly, 30 µg of lysate supernatant was separated
by 12% SDS/polyacrylamide gel electrophoresis and transferred to Polyvinylidene fluoride or
nitrocellulose membrane. Immunoblotting was performed as has been previously described [43].
Chemiluminescence detection was performed with the Amersham ECL or ECL plus detection kit,
according to the manufacturer’s instructions (Amersham, Piscataway, NJ).
3.4. Measurement of HO activity
HO activity was assayed as previously described [43]. Bilirubin, the end product of heme
degradation, is extracted with chloroform and its concentration was determined spectrophotometrically
(Perkin-Elmer Dual UV/VIS Beam Spectrophotometer Lambda 25) using the difference in absorbance
between λ 460 nm to λ 530 nm with an absorption coefficient of 40 mM-1 cm-1.
3.5. Plasma Adiponectin measurement
The high molecular weight (HMW) form of Adiponectin was determined using an ELISA assay
(Pierce Biotechnology Inc., Woburn, MA) as described previously [43,44].
3.6. Measurement of vascular activity
Femoral arteries were isolated and connective tissue was removed. Rings measuring 2 mm in length
were made from the arteries and incubated in individually thermostated (37 ºC) DMT myograph baths
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(DMT, Atlanta, GA) with a passive tension of 1 g for 1 hour in Krebs bicarbonate buffer (pH 7.4)
containing the following (mM): 118 NaCl, 4.7 KCl, 1.5 CaCl2, 25 NaHCO3, 1.1 MgSO4, 1.2 KH2PO4,
and 5.6 glucose, gassed with 21% O2-5%CO2 (balance N2). Force was recorded from force
displacement transducers via AD Instrument’s Powerlab system, running Chart 5 software. After I
hour of equilibration, we calculated, using a cumulative curve, the concentration of phenylephrine (PE)
that determined 70% contraction. Contracted vessels were then given increasing doses of acetylcholine
(Ach) (1 nM-10 µM).
3.7. Measurement of O2- production in the kidney
Previously described methods [55] were used. Homogenized kidney samples of SHRs were placed
in plastic scintillation minivials containing 5 µm lucigenin for detection of O2- and other additions, in a
final volume of 1 ml of air-equilibrated Krebs solution buffered with 10 mmol/L HEPES-NaOH (pH
7.4). Lucigenin chemiluminescence was measured in a liquid scintillation counter (LS6000lC,
Beckman Coulter, Inc, Fullerton, CA) at 37ºC and data reported as counts/min per milligram of protein
after background subtraction.
3.8. Detection and quantification of circulating endothelial cells
For immunomagnetic isolation and quantification of circulating endothelial cells (CEC), we used
monodispersed magnetizable particles (Dynabeads CELLection Pan Mouse IgG kit) obtained from
Invitrogen (Carlsbad, CA). The 4.5 µm diameter polystyrene beads were coated with affinity-purified
pan-anti-mouse immunoglobin G1 covalently bound to the surface. The beads were washed, according
to the instructions provided by the manufacturer, with a strong magnet (MPC6, Dynal) used to remove
sodium azide. Typically, 100 µL of bead suspension was coated noncovalently with 10 µg/mL RECA1 (Novus Biologicals, Littleton, CO), a pan-rat EL-specific monoclonal antibody diluted 1:10 in PBSBSA (0.1%) by overnight incubation at 4ºC with head-over-head agitation. After three washes with
PBS-BSA to remove excess antibodies, the beads were resuspended in buffer until use. RECAuncovered particles were used as a negative control. If the beads were stored for an extended period of
time, 0.1% sodium azide was added to the buffer. Beads and target cells were incubated for 1.5 hours
at 4ºC on a rotator. The amount of beads (4x108/ml) was in great excess of target cells (>2,000 beads
per target cell). Separation of beads and rosetted cells from the blood samples required a minimum
exposure of 1 minute to the magnet. Three washes were performed to completely remove nonrosetted
cells. After the third wash, rosetted cells were recovered in a solution of acridine orange (a viral
fluorescent dye at a final concentration of 5µg/mL in PBS, 150 µL) and subjected to fluorescence
microscopy (Olympus 1X81 F).
3.9. Statistical analysis
Data are presented as mean±SEM for the number of experiments. Statistical significance (p<0.05)
between experimental groups was determined by the Fisher method of analysis of multiple

Int. J. Mol. Sci. 2008, 9

2402

comparisons. For comparison between treatment groups, the null hypothesis was tested by a singlefactor ANOVA for multiple groups or unpaired t test for two groups.
4. Conclusions
These results strongly suggest that the pharmacological induction of HO-1 combined with increased
adiponectin levels in diabetic hypertensive rats alters the phenotype through a reduction in oxidative
stress, thereby permitting endothelial cells to maintain an anti-apoptotic environment through
increased expression of anti-apoptotic proteins and the restoration of endothelial responses thus
preventing hypertension.
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